Ketogenic therapy: The experience of 14 adult brain tumour patients supported by Matthew’s Friends.

S. Wood, C. Zabilowicz, V. Aldridge, K. Sheen, E. Williams, M. Williams

WHAT IS A KETONIC DIET?
• A ketogenic diet (KD) is low in carbohydrate, adequate in protein and high in fat.
• The reduced availability of carbohydrate (glucose) leads to increased fatty acid oxidation in the liver, ketones circulating in the bloodstream and adaptive changes in many metabolic pathways.

Why there is increasing interest in ketogenic diet as an adjuvant therapy for brain tumours and associated symptom management? (1).
• Healthy cells readily use ketones as a fuel source but tumour cells are considered less adaptive and may be disadvantaged by the KD fuel shift.
• KD may provide a means to exploit the metabolic dysregulation and associated pathway changes known to feature in most tumour cells.
• KD is an effective anticonvulsant therapy with a low side effect profile (2).

Table 1:
Summary: The 14 brain tumour cases returning questionnaires

**TIME ON KD**
- 9-57 months - mean 19.7 months at June 2016

**MEDICAL THERAPY WHILE ON KD**
- Chemo-radiation [4]
- None [4]
- Chemotherapy [2]
- Surgery [5]
- Radiotherapy [2]

**OUTCOMES JUNE 2016**
- 5 alive & well (1 GBM, 4 Astrocytoma), 1 Oligodendroglioma
- 1 died (1 GBM, 1 Medulloblastoma, 1 Oligodendroglioma)
- 8 alive & well (3 GBM, 4 Astrocytoma, 1 Oligodendroglioma)

**WHAT KD SUPPORT is available for UK brain tumour patients?**
• Between 2011 and 2016, Matthew’s Friends provided charitably funded specialist dietetic support to over 50 adults from across the UK and Ireland, helping patients to explore KD therapy as a component of their brain tumour management. There are no NHS ketogenic therapy services for these patients. A KD requires individualised prescribing, monitoring and adjustment to optimise outcomes.

Learning from the patients’ experience of KD...
• A questionnaire was devised to gather information on the experiences, thoughts and feelings in relation to pursuit of KD.
• It was sent to 23 patients (n=10 in Sep. 2014, n=13 in Nov. 2015) receiving charitable support.

The questionnaire response:
• 14 (60%) completed and returned
• 9 (40%) no response

**SUMMARY OF RESPONSES**

**SEIZURES: any changes?**
- 2 progression of disease (2 Oligodendroglioma)
- 4 died (2 GBM, 1 Medulloblastoma, 1 Astrocytoma)
- 8 alive & well (3 GBM, 4 Astrocytoma, 1 Oligodendroglioma)

**FATIGUE: any changes?**
- The majority felt less fatigue on ketogenic therapy, not requiring naps so before, having energy to join in more with family etc.

**GL SYMPTOMS: any changes?**
- GI SYMPTOMS: any changes?
- More fatigued
- Feeling negative
- Constipation or N/A

**BLOOD MONITORING: was it useful?**
- Blood glucose and ketone monitoring was found to be useful by all but one patient, although all reported routinely associated with seeing results.

**What was your primary reason for starting ketogenic therapy?**
- Prolonging survival was the reason most often cited, with seizure control, management of tumour progression and management of fatigue also of relevance.
- Two indicated that family pressure played a part in starting ketogenic therapy.

**Have you found ketogenic therapy easy?**
- Despite 12/14 not finding KD too easy, all had been on KD for 8-57 months

**DISCUSSION**

Seizure and fatigue management:
• Those experiencing seizures prior to KD gained evident benefits from their KD in terms of reduced frequency, reduced intensity and shorter recovery time.
• Those experiencing fatigue prior to KD reported a significant improvement in energy levels with less reliance on daytime naps.

Tumour/ KD related monitoring:
• The most accurate method available for glioma patients to track the metabolic shift associated with KD is blood glucose and ketone monitoring. A ratio 1.5-2.1 of blood glucose:ketones is recommended eg. glucose 4.4mmol/l coinciding with ketones 2-4mmol/l (4). Adults can find these levels challenging to achieve.
• There is a need for tumour-specific markers of KD effect so that the therapy can be initiated, adjusted and weaned in accordance with these.

Impact on the tumour:
• Most stated that their reason for starting a KD was to prolong survival.
• To date, the relatively small amount of preclinical and clinical evidence has focussed on the impact of KD on malignant tumours (3). Any potential to influence the growth and progression of low grade brain tumours has yet to be explored.

**CONCLUSION**

Neuro-oncology teams need to be made aware of the potential for KD to deliver improvements in seizures and fatigue where medications have failed.
• KD is an option for those keen to play an active part in their glioma therapy.
• Clinical trials are required (UK trial in the planning stages) to explore KD delivery, monitoring and outcomes in a range of tumour types.

**REFERENCES**

ADDITIONAL COMMENTS ABOUT THEIR KD EXPERIENCE:
"Since starting the diet I feel that I have more energy because I am not up all night with headaches. My mood and variability is much improved... my family has noticed.""My mood is generally better as the diet gives me hope. I am less anxious about focal seizures and are therefore more inclined to see friends which is important to me. I do get frustrated as there (are) lots of extra things for me to do such as writing & monitoring what I am doing, but understand that it is necessary if I want things to improve.""Before the ketogenic therapy, I had no control of my brain tumour, but now I am trying to control it. Just by doing that, whether it is successful or not, makes me feel good. Empowering."